Adolescence marks a challenging time in diabetes care (1). Automated insulin delivery has the potential to overcome some of the barriers, such as missed meal boluses and nocturnal hypoglycemia. The University of Virginia Unified Safety System (USS) is one of the most tested control-to-range approaches and operates on an Android-based system that uses a Dexcom G4 PLATINUM Share glucose sensor and Roche Accu-Chek pump (2). The objective of this study was to test the efficacy of USS in day-and-night closed-loop control (CLC) in adolescents with type 1 diabetes at camp, where large meals and physical activity challenge glucose control. In this study, eligible subjects with type 1 diabetes on pump therapy were randomized to either CLC ( n = 17) or sensor-augmented pump (SAP) ( n = 16) for 5 days. There was no A1C restriction. Clinical characteristics of the 33 subjects include mean ± SD (min–max) age of 17.9 ± 5.5 years (10.1–35.0), weight 68 ± 17 kg (37.3–104.3), A1C …
No takes yet. Share an insight, caveat, or question.
Ly et al. (2016) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: